Nasus Pharma Ltd (NSRX)

$NSRX Time is ticking fast . Q4/2026 is coming soon . Then this stock will explode massively. Buy and hold tight and be patient. 9-10$ is coming in Q4/2026 .

Nasus Pharma (NYSE American: $NSRX ) brings its Nasax intranasal drug delivery technology for medical emergencies to the Life Sciences Virtual Investor Forum on June 25 at 11:00 AM ET. Nasus Pharma Ltd. (NYSE American: NSRX) presents at the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, at 11:00 AM ET on Thursday, June 25, 2026, in a session moderated by John Vandermosten, CFA, Senior Analyst at Zacks Small Cap Research. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5397572/nasus-pharma-ltd-nyse-american-nsrx?utm_source=b2i&utm_medium=marketing&utm_campaign=0624LifeSciencesForumVIC Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76 Dan Teleman, CEO, presents for Nasus Pharma alongside SVP and CFO Eyal Rubin. Teleman joined in January 2025 with over 20 years in the pharmaceutical industry, most recently as CEO of Pharma Two B and previously CEO of Atox Bio for 12 years, and holds an MBA from Duke University's Fuqua School of Business. Rubin brings more than 20 years of finance and capital markets experience, including CFO roles at Protalix BioTherapeutics and BrainStorm Cell Therapeutics. Nasus Pharma is a clinical-stage biopharmaceutical company developing innovative intranasal drug delivery products. Uniquely positioned to address medical emergencies, its proprietary Nasax technology is designed to enhance intranasal drug absorption with potential for longer product shelf life through a unique powder formulation. Learn more at https://ir.nasuspharma.com/. Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

$NSRX NS002 June KOL Event https://buff.ly/k5rnB6i

$NSRX CEO purchased 6,550 shares at $3.10 for a total of $20,305. Teleman Dan Benjamin now owns 163,541 shares. https://ceo-buys.com

$NSRX This stock should go higher based on phase 3 study witch will start in September and will end before year end 2026 in December . I see 9-10$ in October and 20$ in December after FDA approval. Hold tight smart investors .

$NSRX is reporting positive preclinical pharmacokinetic and safety results for its intranasal ondansetron candidate NS003.

$NSRX 📊💰

Among micro-cap biotech names, $NSRX has been attracting growing attention. The company's lead candidate, NS002, is a needle-free intranasal epinephrine powder designed for the $2B+ anaphylaxis treatment market, offering a potential alternative to traditional injectable products. Reported Phase 2 results showed: • Median time to therapeutic levels: 1.69 minutes • EpiPen comparison: 3.42 minutes • 91% reached therapeutic concentration within 5 minutes • No serious adverse events reported Beyond NS002, the company is advancing multiple pipeline candidates. Key milestones investors are watching include: • IND submission expected in Q3 2026 • Pivotal study planned for Q4 2026 • Potential data readout around Q1 2027 The company also completed a $15M private financing earlier this year to support clinical development. With a market capitalization of roughly $60M, future valuation changes will likely depend on clinical execution, regulatory progress, and upcoming trial results.

$NSRX 👀 Interesting micro-cap biotech setup. ✅ Higher lows forming ✅ Triangle breakout developing ✅ OBV improving ✅ TTM downside momentum fading ✅ Buyers defending the $2 area Meanwhile: • Positive NS002 Phase 2 data • Proprietary intranasal platform • $15M cash raise extending runway into 2027 Only ~$28M market cap. A clean break over $3.50-$4.00 could change the entire chart structure. Worth watching. 👀 $NSRX #biotech #stocks #trading Disclaimer: https://stockresearchtoday.com/nsrx/